I hope I’m right too, also simply posing the question. Nothing is a sure thing but it just seems like it would make more sense to be concerned if the company had a track record of failing to get generics approved. Thus far, that has not been the case.
I am optimistic that the growing revenues, the facility expansion, the multiple ANDAs under review, and the further ANDAs in trials and formulation will lead to a higher PPS.